NEWSROOM

Biotechnology

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share, marking the fourth consecutive quarter of profitability Preliminary Q4 2024 Adjusted EBITDA of $11.1 Million Financial Results Conference Call and Webcast to be held on April 14, 2025 at 4:30 pm ET POMPANO BEACH, FL, April 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc....

read more
Aemetis Biogas Monthly RNG Production Increased by 55% in March

Aemetis Biogas Monthly RNG Production Increased by 55% in March

Sales of LCFS credits and D3 RINs completed at the end of Q1 CUPERTINO, Calif., April 08, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity renewable fuels, announced today that its production of renewable natural gas (RNG) increased 55% in March compared to February. RNG production from anaerobic dairy digesters increases during periods of warmer weather due to improved temperatures for...

read more
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 08, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that it will release its fourth quarter and full year 2024 financial results on Monday, April 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview...

read more
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Topline Results Expected Q2 2025 Listen: PITTSBURGH, April 08, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The Phase 2a trial has now fully...

read more
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

POMPANO BEACH, Fla., April 1, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces it has filed for an extension to submit its annual report for the year ended December 31, 2024 to the OTC The company is currently undergoing a mandatory Securities Exchange Commission (SEC) review process related to its Form 10 registration...

read more
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

BioStem Announces Notice of Allowance for Two U.S. Patent Applications

Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of...

read more
Digital Utilities Ventures Secures $3.4M Contract to Deploy Easy FEN™ Sustainable Agriculture Units in Africa

Digital Utilities Ventures Secures $3.4M Contract to Deploy Easy FEN™ Sustainable Agriculture Units in Africa

Pioneering Green Technology to Transform Food Security and Agricultural Productivity Key Highlights: Sustainable Agriculture Solution for AfricaDigital Utilities Ventures (DUTV) has secured a $3.4 million contract to deploy its patent pending Easy FEN™ modular units in Northern Africa. These advanced systems will convert 35,000 tons of biomass and food waste annually into 5.4 million gallons of Terreplenish®, an organic liquid microbial fertilizer. This initiative supports sustainable farming...

read more
Digital Utilities Ventures Acquires Lifestyle Dock Company, and Expands Market Reach for Easy NanoVoid™ Technology

Digital Utilities Ventures Acquires Lifestyle Dock Company, and Expands Market Reach for Easy NanoVoid™ Technology

Acquisition Provides Strategic East Coast Manufacturing Facility and Strengthens International Distribution Capabilities Key Highlights: Strategic Acquisition for Market Expansion: Digital Utilities Ventures (OTC: DUTV) acquires Lifestyle Dock Company (LDC), unlocking a potential $3.4 million in additional revenue and expanding the reach of its patented Easy NanoVoid™ water purification technology. This acquisition enhances DUTV’s presence in the luxury dock and marina market, introducing...

read more
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded clinical kitted product development with $50+ million in equity raises Advanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to...

read more
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

IRVINE, Calif., March 18, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration: Register here An archived...

read more
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers

Study comparing BioStem’s proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinical efficacy to support market expansion POMPANO BEACH, FL, February 24, 2025 - PRISM MediaWire - BioStem Technologies, Inc. a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces Institutional Review Board (IRB) approval for a clinical...

read more
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

IRVINE, Calif., Feb. 11, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to...

read more
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 - PRISM...

read more
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte Prices $29.1 Million Equity Offering

Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE...

read more
Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 6, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),...

read more
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

PITTSBURGH, February 6, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP). LP-310 is an innovative, localized therapy formulated to...

read more
Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trial CLARITY is a prospective, randomized, multicenter study to validate Nociscan’s ability to improve surgical outcomes Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Broomfield, CO, February 4, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

read more
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference

Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI)  NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain BROOMFIELD, Colo., January 31, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain,...

read more
Argentum 47, Inc. Announces Acquisition of Marelius Biopharma Group, Divestiture of Argentum Data Solutions, and Leadership Transition

Argentum 47, Inc. Announces Acquisition of Marelius Biopharma Group, Divestiture of Argentum Data Solutions, and Leadership Transition

Las Vegas, NV, January 21, 2025 - PRISM MediaWire - Argentum 47, Inc. (OTC PINK: ARGQ) (“Argentum” or the “Company”) today announced a series of transformative developments, including the acquisition of Marelius Biopharma Group (MBG), the divestiture of Argentum Data Solutions, and a leadership transition aimed at strengthening the Company’s strategic focus and shareholder value. Acquisition of Marelius Biopharma Group Argentum has acquired Marelius Biopharma Group (MBG), a UK-based company...

read more
Digital Utilities Ventures Secures $3.4M Contract to Deploy Easy FEN™ Sustainable Agriculture Units in Africa

Digital Utilities Ventures, Inc. Announces Strategic Partnership with TradersQue LLC to Support Growth and Expansion Initiatives

Mankato, MN, January 15th, 2025 - PRISM MediaWire - Digital Utilities Ventures (OTC: DUTV), a green solutions company focused on regenerative agriculture and clean water technologies, is pleased to announce a strategic partnership with TradersQue LLC (www.TradersQue.com). The collaboration aims to leverage TradersQue’s innovative business solutions to support DUTV’s ongoing growth and expansion efforts across the Agricultural and other new markets. This partnership will provide DUTV with...

read more
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

POMPANO BEACH, Fla., January 13, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced selected preliminary financial results for the fiscal fourth quarter and full year ended December 31, 2024. 2024 Preliminary Fourth Quarter and Year End Results: Fourth quarter net revenue is expected to...

read more
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Company to present at 3:00 p.m. PT on Tuesday, January 14, at the Hilton San Francisco Union Square New York, NY, January 8, 2025 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s, and Parkinson’s disease, announces that it will present at Biotech Showcase 2025, an event expected to include over 3,200 healthcare professionals with more than 1,200...

read more
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business development efforts and strategic partnerships Irvine, Calif., Jan. 8, 2025 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company’s Consulting Chief Medical Officer. In this part-time role, he will support a...

read more
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., January 8, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces the initiation of the BR-AM-DFU (BioREtain® Amniotic Membrane - Diabetic Foot Ulcers) clinical trial to evaluate Vendaje® versus...

read more
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-Code Up to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than 10,000 patients per year in the US.1 From time of onset of dnDSA, 24%...

read more
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies CEO to Present at Biotech Showcase 2025

Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025 POMPANO BEACH, Florida, January 2, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, the Company’s Chief Executive Officer, will present a corporate overview and update at the Biotech Showcase 2025 conference, which is...

read more
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

January 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 - PRISM MediaWire - Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13 - 16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors....

read more
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board

Klotho Neurosciences, Inc. continues to strengthen its advisory teams with recent new additions of Neuroscience and Big Pharma leaders to Scientific Advisory Board and Board of Directors New York, NY, December 9, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s and Parkinson’s disease is proud to announce the appointment of Dr. Merit Cudkowicz,...

read more
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

IRVINE, Calif., Dec. 04, 2024 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number...

read more
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Former Merck USA President Joins Klotho Neurosciences’ Board of Directors

Highly Accomplished Pharmaceutical Leader, Riad El-Dada, Further Enhances Board Expertise NEW YORK, Dec. 03, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer’s, and Parkinson’s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850